Industry Research Reports: Market study Report: Deferasirox - Key patent, SPC, and data exclusivity expiry Market Size

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/deferasirox-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage

This Pipeline Selector report covers Deferasirox
Deferasirox indications: Treatment of chronic iron overload due to blood transfusions or in patients with non-transfusion dependent thalassaemia; Management of chronic iron overload in transfusion-dependent anaemias
Deferasirox innovator: Novartis (Exjade)

Examples of information found in this online report include:

Includes key patent publications for 44 countries (see list below)
Contains SPC protection for every EU state plus patent term extensions in other countries
Data exclusivity calculated on a country by country basis
Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
DMF & Paragraph IV filings
Litigation alerts
Marketing authorisation holders in selected territories
Patent risk analysis via graphical display of data from patent filings
Hyper-linking to crucial patent documents and national registries enabling data verification